Prot# 114-21: A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination with Rituxan® for Patients with Relapsed or Refractory Follicular Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date1/14/03 → 1/1/11

Funding

  • IDEC Pharmaceuticals Corporation (114-21)